• Telix reported a 22% YoY increase in revenue to $477M
• Precision Medicine revenue increased by 27% YoY to $388M
• Strong demand for Illuccix and Gozellix across global markets
• Net profit increased by $41M YoY to $38M
• Cash balance up 78% to $252M

Telix Pharmaceuticals Ltd announced its H1 2026 interim results, highlighting a 22% year-over-year (YoY) increase in revenue to $477 million. The Precision Medicine segment saw a 27% YoY revenue growth to $388 million, driven by strong demand for Illuccix and Gozellix across global markets. Net profit increased by $41 million YoY to $38 million, and the cash balance rose 78% to $252 million. The company also reported a gross margin of 55%, up 2% YoY, and an EBITDA of $52 million, up 146% YoY. Telix is on track to deliver revenue in line with the upper end of its FY 2026 guidance of $950M - $970M, with Precision Medicine expected to contribute significantly to this growth.

FY 2026 revenue guidance: $950M to $970M, R&D guidance: $230M to $270M

Telix anticipates continued growth and is reinvesting earnings to position the company for long-term success. The company expects revenue to come in at the upper end of guidance, with potential upside pending regulatory approvals.